Plain-English translation of NCT06603246 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new inhaled medication called to see if it is safe and effective for people with chronic lung diseases that involve too much mucus production—specifically bronchiectasis (damaged airways) and COPD (chronic obstructive pulmonary disease). Researchers want to understand how well this medication works and what side effects it may cause.
People with these lung conditions struggle with excess mucus that clogs their airways, making it hard to breathe. Current treatments don't always work well enough, so doctors are testing this new medication to see if it can help clear mucus and improve breathing.
You likely qualify if…
You likely don't qualify if…
Depending on which group you are assigned to, you will use the inhaled medication once or twice daily for either 1–2 days or 14 days. Some participants will start with a low dose and move to a higher dose, while others will stay on a low dose throughout. You will visit the study clinic for check-ins, breathing tests, and possibly to provide sputum (mucus) and blood samples so researchers can measure how the medication is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States